Clinical experience with oral topotecan in relapsed small cell lung cancer patients following irinotecan-platinum chemotherapy
Navneet Singh, Venkata Nagarjuna Maturu, Inderpaul Singh Sehgal
Citation Information :
Singh N, Maturu VN, Sehgal IS. Clinical experience with oral topotecan in relapsed small cell lung cancer patients following irinotecan-platinum chemotherapy. J Postgrad Med Edu Res 2016; 50 (2):110-111.
CC BY-ND 4.0
Copyright © 2016; The Author(s).
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006 Dec 1;24(34):5441-5447.
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007 May 20;25(15): 2086-2092.
Management of advanced lung cancer in resource-constrained settings: a perspective from India. Expert Rev Anticancer Ther 2012 Nov;12(11):1479-1495.
Tumor cavitation among lung cancer patients receiving firstline chemotherapy at a tertiary care centre in India: association with histology and overall survival. Med Oncol 2013; 30(3):602
Intercycle delays during chemotherapy of non-small cell lung cancer in a health care resource-constrained setting and their effect on overall survival. J Thorac Oncol 2010 Feb;5(2):236-239.
Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer. Cancer Chemother Pharmacol 2008 Nov;62(6):1009-1014.